On March 16, 2026, Soleno Therapeutics Inc. filed an 8-K report with the Securities and Exchange Commission (SEC) detailing amendments to its bylaws. The changes were approved by the Board of Directors following recommendations from the Nominating and Corporate Governance Committee. The amendments primarily focus on updating advance notice provisions for stockholder proposals and nominations, aligning the bylaws with recent changes in Delaware law, and incorporating certain governance updates, including a forum selection provision. The updated bylaws also include technical and clarifying changes to enhance clarity and compliance. The full text of the Amended and Restated Bylaws is attached as Exhibit 3.1 to the filing. This filing is part of the company's ongoing efforts to ensure that its governance practices remain current and effective, reflecting best practices in corporate governance. The amendments are not expected to have a significant impact on the company's stock price, as they are largely administrative in nature and do not involve any changes to the company's operational strategy or financial structure.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.